Ashley PharmD - Merus BV Senior Affairs
| MRUS Stock | USD 45.39 0.10 0.22% |
Executive
Ashley PharmD is Senior Affairs of Merus BV
| Address | Uppsalalaan 17, Utrecht, Netherlands, 3584 CT |
| Phone | 31 30 253 8800 |
| Web | https://www.merus.nl |
Merus BV Management Efficiency
The company has return on total asset (ROA) of (0.216) % which means that it has lost $0.216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.446) %, meaning that it created substantial loss on money invested by shareholders. Merus BV's management efficiency ratios could be used to measure how well Merus BV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to gain to -0.38 in 2024. At this time, Merus BV's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 94.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andrew Schwendenman | Replimune Group | 48 | |
| Venkatesh Srinivasan | Sutro Biopharma | 62 | |
| David MBA | Inhibrx | N/A | |
| Paul MBA | Vaxcyte | 63 | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Wes Trotter | Kronos Bio | N/A | |
| Mollie MD | Kura Oncology | N/A | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Paul Bullock | Replimune Group | N/A | |
| Priya Raina | AnaptysBio | N/A | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Mohammad Masjedizadeh | Protagonist Therapeutics | N/A | |
| Margaux Bennett | Kronos Bio | N/A | |
| Charbel PharmD | Inhibrx | N/A | |
| Martin Dahl | AnaptysBio | N/A | |
| Pamela Esposito | Replimune Group | 50 | |
| Colin Love | Replimune Group | 66 | |
| JD Esq | Kura Oncology | 53 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.22 |
Merus BV Leadership Team
Elected by the shareholders, the Merus BV's board of directors comprises two types of representatives: Merus BV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merus. The board's role is to monitor Merus BV's management team and ensure that shareholders' interests are well served. Merus BV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merus BV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ashley PharmD, Senior Affairs | ||
| Kathleen Farren, IR Officer | ||
| Gregory Perry, Chief Officer | ||
| Hennie Hoogenboom, CoFounder Advisor | ||
| Alexander Bakker, Chief VP | ||
| Peter JD, Company EVP | ||
| Cecilia Geuijen, Chief VP | ||
| Jillian Connell, VP Communications | ||
| Sven MD, President, CEO | ||
| Cornelis Kruif, CTO VP | ||
| Hui Liu, Chief Business Officer and Head of Merus U.S., Executive Vice President | ||
| Harry Shuman, Chief Officer | ||
| Andrew MD, Consultant | ||
| Audrey Bergan, Chief Officer | ||
| Shannon Campbell, Executive Officer |
Merus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merus BV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (6.14) % | ||||
| Current Valuation | 2.49 B | ||||
| Shares Outstanding | 68.46 M | ||||
| Shares Owned By Insiders | 2.00 % | ||||
| Shares Owned By Institutions | 98.00 % | ||||
| Number Of Shares Shorted | 8.66 M | ||||
| Price To Earning | (4.47) X | ||||
| Price To Book | 4.43 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.